Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01538823 · ClinicalTrials.gov registry record
Urine Proteome of Surgical Patients and Healthy Volunteers
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 664
- Enrollment target
NCT01538823: Completed study, sponsored by Washington University School of Medicine.
NCT01538823 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 664 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01538823 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 664 participants
- Enrollment target
Study Summary
The purpose of this study is to define early urinary biomarkers for diagnosis and prognosis of Renal Cell Carcinoma (RCC) with subsequent development of reliable, cost-effective, screening techniques.
Primary Outcome
The overall objective of our study is to find and evaluate additional novel biomarkers, predictive of disease, that are present and measurable in whole urine of patients undergoing surgery for renal cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 664 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-07 |
What the finished NCT01538823 record still lists
NCT01538823 is an observational study that tracks outcomes without assigning an intervention. The registered 664 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01538823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01538823 about?
NCT01538823 is a clinical study titled "Urine Proteome of Surgical Patients and Healthy Volunteers". The purpose of this study is to define early urinary biomarkers for diagnosis and prognosis of Renal Cell Carcinoma (RCC) with subsequent development of reliable, cost-effective, screening techniques.
What is the current status of trial NCT01538823?
This trial is currently completed. The enrollment target is 664 participants. The study started on 2012-02. Estimated completion is 2016-07.
Who is sponsoring clinical trial NCT01538823?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT07164443 · 663 participants · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia